Circus SE Successfully Acquires Agentic AI Company FullyAI
MUNICH--(BUSINESS WIRE)-- Circus SE (XETRA: CA1), a global technology leader in AI-robotics for the food service industry, today announces the successful acquisition of agentic AI company FullyAI, marking a major milestone in its mission to build a unified intelligence layer across its robotics and software. FullyAI will become the cognitive engine of the Circus ecosystem — starting with a fully integrated AI-powered voice ordering terminal and expanding into real-time operational decision-making, predictive maintenance, autonomous optimization, and highly personalized user experiences across the Circus AI-Software and robotics ecosystem.
By leveraging billions of data points at scale from Circus' patented CA-1 meal supply robots, FullyAI unlocks a continuously learning, self-improving intelligence layer that connects every robot and software process in real time.
Integrated with Circus proprietary systems, this unified ecosystem understands context, demand, and behavioral patterns through multiple owned data streams — including inventory and procurement systems, customer profiling, and real-time robot operations. This continuous flow of insights forms the foundation for the first ever global nutrition intelligence network — allowing Circus systems to anticipate demand, adapt dynamically, and scale precision nutrition worldwide. The operational layer (CircusOS), the physical AI-robotics layer (CA-1), and the intelligence layer (FullyAI) now work together seamlessly.
'FullyAI further advances our autonomous systems and software into a true intelligent ecosystem: one that oversees, learns, and predicts. With this acquisition, we are laying the groundwork for a global nutrition intelligence layer — comparable to what Tesla has built in autonomous driving or Meta in social data — leveraging every data point to better understand complex nutrition patterns. With the acquisition of Fully, we are also expanding our growing stack of proprietary IP in the field of global nutrition autonomy for humans', comments CEO and Founder of Circus SE, Nikolas Bullwinkel on the successful acquisition.
As part of the acquisition, the FullyAI engineering team and management joined Circus. Niklas von Weihe, previously working closely with Meta's (Nasdaq: META) advanced AI teams, joins as Director of AI. Minh Dao, former CEO of a leading growth and brand consultancy with clients like Tesla (Nasdaq: TSLA), Google (Nasdaq: GOOGL), and McDonald's (NYSE: MCD), joins as VP of Growth, overseeing new product verticals and brand scale initiatives.
The transaction was completed on the terms defined in the ad hoc announcement dated January 12, 2025, including the issuance of 400,000 new shares with a 36-month lock-up period. The next steps required under company law to implement the acquisition are expected to be completed by the end of June.
For more information, visit: www.circus-group.com/fully-ai
About Circus SE
Circus SE (XETRA: CA1) is a global technology company in the field of embodied AI and AI software for the food service industry, driving innovation and autonomy in labor-intensive sectors. With its core product, the CA-1 robot, Circus is a pioneer in applying embodied AI, integrating cutting-edge technologies into real-world operations, and transforming the food service industry. By combining advanced robotics, AI-driven software, and a mission to solve global challenges, Circus is shaping the future of autonomous systems and redefining human-AI collaboration. Headquartered in Germany and with a rapidly growing international presence, Circus leads the next generation of AI applications.
About FullyAI
FullyAI is the agentic AI company powering the intelligence layer of Circus SE's robotics and software ecosystem. Now fully integrated into Circus following its acquisition in May 2025, FullyAI enables real-time operational decision-making, predictive maintenance, and personalized user experiences by processing billions of data points from CA-1 autonomous cooking robots. Acting as the cognitive engine behind the system, FullyAI transforms data streams into actionable insights, helping Circus build the world's first global nutrition intelligence network and scale precision nutrition through autonomous food systems.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Why Concrete Pumping Stock Is Down Big Today
Concrete Pumping delivered an unexpected quarterly loss and lowered full-year expectations. The company is facing a slowdown in construction due to macro headwinds and bad weather. There is balance sheet risk here, but Concrete Pumping could be an attractive option for investors who believe spending on infrastructure will pick up over time. 10 stocks we like better than Concrete Pumping › Economic headwinds and bad weather conspired to cut construction activity, which in turn ate into results at Concrete Pumping Holdings (NASDAQ: BBCP). Shares of the multinational concrete provider traded down 17% as of 11 a.m. ET after the company reported results that fell short of Wall Street expectations. Concrete Pumping plays a key part in the construction supply chain, providing concrete and concrete waste management services at job sites in the U.S. and in the United Kingdom. But there is only so much the company can do when demand for concrete slows, a scenario that played out in the most recent quarter. The company lost $0.01 per share on revenue of $93.96 million in its fiscal second quarter ending April 30, compared to Wall Street's forecast for a $0.04 per-share profit on sales of $99 million. Concrete Pumping did a good job keeping costs in line and gross margin is actually up slightly for the first six months of fiscal 2025 compared to a year ago, but the macro story was too much to overcome. "In the second quarter, we continued to navigate a challenging construction environment, marked by persistent macroeconomic headwinds and regional weather disruptions," CEO Bruce Young said in a statement. Management is not anticipating an immediate bounce back. Concrete Pumping cut its full-year revenue forecast to $380 million to $390 million, from $425 million to $445 million, saying it is not forecasting a "meaningful" recovery in the construction market until its fiscal 2026. Even with the declines, Concrete Pumping is still a long-term winner, up 62% over the past five years. The company has a lot of debt, $387 million at quarter's end, compared to a market capitalization of $317 million, but management remains confident enough in cash flows to pursue opportunistic acquisitions and boost its share buyback program by $15 million. For investors who are bullish long-term on the need for infrastructure revitalization in the U.S. and Western Europe and who are willing to ride out a near-term storm, this decline in Concrete Pumping shares could be viewed as a buying opportunity. Before you buy stock in Concrete Pumping, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Concrete Pumping wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,395!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $858,011!* Now, it's worth noting Stock Advisor's total average return is 997% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Lou Whiteman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Concrete Pumping Stock Is Down Big Today was originally published by The Motley Fool
Yahoo
12 minutes ago
- Yahoo
Omada Health goes public at $23 per share, marking second major digital health IPO in 2025
Omada Health (OMDA) has become the second major digital health company to debut on the public markets this year, with an initial public offering valued at $1.1 billion. The company follows a successful launch of Hinge Health (HNGE) last month, which plays in one of the same markets as Omada: musculoskeletal health guidance. But Omada is better known as a clinical health guidance company for multiple chronic diseases, with an emphasis lately on weight loss management. Omada began trading at $23 per share on the Nasdaq on Friday. By midday, Omada stock traded as high as $28 per share, up 47% from the $19 per share the stock was initially price at. Read more about Omada's opening stock moves and today's market action. The digital health platform has found its footing in the weight management space, though not by offering popular GLP-1 treatments. The company doesn't plan on doing so in the future either, CEO Sean Duffy told Yahoo Finance. Duffy said that's one reason why "the capital markets have, in many ways, asked us to come in" to the public markets. The company has differentiated itself and avoided the pitfalls of an ever-changing GLP-1 market, which was plagued early on by shortages and then disruption after the FDA removed GLP-1s from its shortage list, ending access to copycats of the popular drugs. Omada provides clinical guidance to patients once they leave their doctor's office. It's a concept that Duffy and his co-founders realized was needed more than a decade ago when the weight loss market and technology were very different. When asked if Duffy regretted not going public during the pandemic when digital health was experiencing an investment boom, he said no and added that the company had only begun expanding beyond diabetes into other care areas, including weight loss. "When you're becoming a public company, you want to make sure to have your proof points out there," Duffy said. "In retrospect, it was a great decision." But Omada does have the pandemic to thank for its growth, as it put a spotlight on digital health services. The company has grown its user base through partnerships with large companies that offer the services to employees. In addition, Omada is partnered with pharmacy benefit managers, including CVS (CVS) and Cigna (CI) — the latter of which is also an early investor through its ventures arm. Omada began its journey by serving the needs of diabetics, including a partnership with Abbott (ABT) and users of its Freestyle Libre continuous glucose monitoring devices. It has since expanded to the GLP-1 market by providing the same guidance services, including meal kits and lifestyle change advice, to patients. Still, the company has yet to turn a profit in its 14-year existence. Duffy said the company's losses are decreasing over time, and revenue continues to grow year over year. 'We have a history of net losses, due in part to the significant investments we have made in the design and development of our programs and platform enhancements, and have not yet achieved profitability on an annual basis,' the company said in its S-1 filing. The company stated it incurred net losses of $67.5 million and $47.1 million in 2023 and 2024, respectively. In the first quarter ended March 31 of this year, Omada lost $9.4 million compared to a $19 million loss in the same period a year prior. 'We incurred net losses of $67.5 million and $47.1 million for the years ended December 31, 2023 and 2024, respectively, and $19.0 million and $9.4 million for the three months ended March 31, 2024 and 2025, respectively.' Duffy said he hopes new investors can help guide the company to become a leading platform addressing chronic disease. "It's just a neat moment in time, where the new shareholders that are coming in can help me, and help us, imagine a path ... to bend the curve of disease," he said. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Sign in to access your portfolio
Yahoo
19 minutes ago
- Yahoo
Omada Health CEO talks about IPO and diabetes treatment
Telehealth provider Omada Health (OMDA) raised $150 million in its IPO as the company makes its public debut on the Nasdaq on Friday. Omada Health CEO Sean Duffy sits down with Yahoo Finance senior health reporter Anjalee Khemlani at the Nasdaq MarketSite to speak more about Omada's approach to treating chronic diseases, like diabetes, and its relationship with patients and pharmaceutical companies. To watch more expert insights and analysis on the latest market action, check out more Wealth here. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
